dc.contributor.author |
Kafatos G |
|
dc.contributor.author |
Niepel D |
|
dc.contributor.author |
Lowe K |
|
dc.contributor.author |
Jenkins-Anderson S |
|
dc.contributor.author |
Westhead H |
|
dc.contributor.author |
Tímár, József |
|
dc.contributor.author |
Tóth, Erika |
|
dc.date.accessioned |
2019-06-20T06:22:36Z |
|
dc.date.available |
2019-06-20T06:22:36Z |
|
dc.date.issued |
2017 |
|
dc.identifier.citation |
pagination=751-760;
journalVolume=11;
journalIssueNumber=9;
journalTitle=BIOMARKERS IN MEDICINE; |
|
dc.identifier.uri |
http://repo.lib.semmelweis.hu//handle/123456789/5129 |
|
dc.identifier.uri |
doi:10.2217/bmm-2016-0358 |
|
dc.description.abstract |
AIM: A confirmed wild-type RAS tumor status is commonly required for prescribing anti-EGFR treatment for metastatic colorectal cancer. This noninterventional, observational research project estimated RAS mutation prevalence from real-world sources. MATERIALS & METHODS: Aggregate RAS mutation data were collected from 12 sources in three regions. Each source was analyzed separately; pooled prevalence estimates were then derived from meta-analyses. RESULTS: The pooled RAS mutation prevalence from 4431 tumor samples tested for RAS mutation status was estimated to be 43.6% (95% CI: 38.8-48.5%); ranging from 33.7% (95% CI: 28.4-39.3%) to 54.1% (95% CI: 51.7-56.5%) between sources. CONCLUSION: The RAS mutation prevalence estimates varied among sources. The reasons for this are not clear and highlight the need for further research. |
|
dc.relation.ispartof |
urn:issn:1752-0363 |
|
dc.title |
RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data |
|
dc.type |
Journal Article |
|
dc.date.updated |
2018-03-12T14:24:07Z |
|
dc.language.rfc3066 |
en |
|
dc.identifier.mtmt |
3273953 |
|
dc.identifier.wos |
000411390700008 |
|
dc.identifier.pubmed |
28747067 |
|
dc.contributor.department |
SE/AOK/I/II. Sz. Patológiai Intézet |
|
dc.contributor.institution |
Semmelweis Egyetem |
|